Comparison

Human NKG2A / CD159a Protein, Fc Tag European Partner

Item no. NKA-H526c-1mg
Manufacturer ACROBiosystems
Amount 500 ug x 2
Quantity options 100 ug 500 ug x 2
Category
Type Proteins Recombinant
Format Solid
Specific against Human (Homo sapiens)
Host HEK293
Conjugate/Tag Unconjugated, Fc
Purity 95%
Citations (1) Sun C, et al. Oncoimmunology. 2016. 6(1):e1264562. (2) McWilliams EM, et al. Oncoimmunology. 2016. 5(10). (3) van Montfoort N, et al. Cell. 2018. 175(7):1744-1755.
NCBI NP_002250.1
ECLASS 10.1 32160409
ECLASS 11.0 32160409
UNSPSC 12352202
Alias NKG2A,CD159a,KLRC1,NK cell receptor A
Shipping Condition Room temperature
Available
Manufacturer - Category
Protein
Manufacturer - Conjugate / Tag
N-Fc, Unconjugated
Shipping Temperature
RT
Storage Conditions
-20°C
Molecular Weight
42.5 kDa
Manufacturer - Format
Powder
Description
NKG2A/CD159a is a transmembrane protein belonging to the CD94/NKG2 family of C-type lectin-like receptors that inhibits innate immune system activation, also known as KLRC1, CD159a, NK cell receptor A and NKG2-A/NKG2-B type II integral membrane protein. NKG2A marks a unique immune effector subset preferentially co-expressing the tissue-resident CD103 molecule, but not immune checkpoint inhibitors. NKG2A blockade therapy operated through CD8 T cells, but not NK cells. The increase in NKG2A expression might be induced by IL-10, which was present at a high level in the plasma of HCC patients. Blocking IL-10 could specifically inhibit NKG2A expression in NK cells. These findings indicate that NKG2A expression is influenced by factors from cancer nests and contributes to NK cell exhaustion, suggesting that NKG2A blockade has the potential to restore immunity against liver tumors by reversing NK cell exhaustion.
Background
NKG2A/CD159a is a transmembrane protein belonging to the CD94/NKG2 family of C-type lectin-like receptors that inhibits innate immune system activation, also known as KLRC1, CD159a, NK cell receptor A and NKG2-A/NKG2-B type II integral membrane protein. NKG2A marks a unique immune effector subset preferentially co-expressing the tissue-resident CD103 molecule, but not immune checkpoint inhibitors. NKG2A blockade therapy operated through CD8 T cells, but not NK cells. The increase in NKG2A expression might be induced by IL-10, which was present at a high level in the plasma of HCC patients. Blocking IL-10 could specifically inhibit NKG2A expression in NK cells. These findings indicate that NKG2A expression is influenced by factors from cancer nests and contributes to NK cell exhaustion, suggesting that NKG2A blockade has the potential to restore immunity against liver tumors by reversing NK cell exhaustion.
Molecule
NKG2A
Exp Region
Pro 94 - Leu 233
Characteristics
This protein carries a human IgG1 Fc tag at the N-terminus. The protein has a calculated MW of 42.5 kDa. The protein migrates as 55-65 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
Endotoxin
1.0 EU per μg
Buffer
Tris with Glycine, Arginine and NaCl, pH7.5
Stability
● -20°C to -70°C for 12 months in lyophilized state
● -70°C for 3 months under sterile conditions after reconstitution._x000D_For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Protectant
trehalose

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Amount: 500 ug x 2
Available: In stock
available

Delivery expected until 2/19/2026 

Compare

Add to wishlist

Get an offer

Request delivery time

Ask a technical question

Submit a bulk request

Questions about this Product?